The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain
Abstract
Cannabidiol, the major psycho-inactive component of cannabis, has substantial anti-inflammatory and immunomodulatory effects. This study investigated its therapeutic potential on neuropathic (sciatic nerve chronic constriction) and inflammatory pain (complete Freund's adjuvant intraplantar injection) in rats. In both models, daily oral treatment with cannabidiol (2.5-20 mg/kg to neuropathic and 20 mg/kg to adjuvant-injected rats) from day 7 to day 14 after the injury, or intraplantar injection, reduced hyperalgesia to thermal and mechanical stimuli. In the neuropathic animals, the anti-hyperalgesic effect of cannabidiol (20 mg/kg) was prevented by the vanilloid antagonist capsazepine (10 mg/kg, i.p.), but not by cannabinoid receptor antagonists. Cannabidiol's activity was associated with a reduction in the content of several mediators, such as prostaglandin E(2) (PGE(2)), lipid peroxide and nitric oxide (NO), and in the over-activity of glutathione-related enzymes. Cannabidiol only reduced the over-expression of constitutive endothelial NO synthase (NOS), without significantly affecting the inducible form (iNOS) in inflamed paw tissues. Cannabidiol had no effect on neuronal and iNOS isoforms in injured sciatic nerve. The compound's efficacy on neuropathic pain was not accompanied by any reduction in nuclear factor-kappaB (NF-kappaB) activation and tumor necrosis factor alpha (TNFalpha) content. The results indicate a potential for therapeutic use of cannabidiol in chronic painful states.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, anti-hyperalgesic effects observed with these compounds are likely to be independent of cannabinoid receptors, and may be mediated through TRPV1.”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [40]
Citations
Cites
Ethical guidelines for investigations of experimental pain in conscious animals.
Zimmermann, M. (1983) · Pain · doi:10.1016/0304-3959(83)90201-4 · Cited by 7,762
A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man
Bennett, G. J., & Xie, Y.-K. (1988) · Pain · doi:10.1016/0304-3959(88)90209-6 · Cited by 5,376
Wendel, A. (1981) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(81)77046-0 · Cited by 3,032
Pharmacology of cannabinoid CB1 and CB2 receptors
Pertwee, R. G. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)82001-3 · Cited by 1,526
Bisogno, T., Hanuš, L., PETROCELLIS, L. D., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Marzo, V. D. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,315
Cannabidiol and (−)Δ 9 -tetrahydrocannabinol are neuroprotective antioxidants
Hampson, A. J., Grimaldi, M., Axelrod, J., & Wink, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8268 · Cited by 850
Subbaramaiah, K., Chung, W. J., Michaluart, P., TELANG, N. T., Tanabe, T., Inoue, H., Jang, M., Pezzuto, J. M., & Dannenberg, A. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.34.21875 · Cited by 786
SR 144528, the First Potent and Selective Antagonist of the CB2 Cannabinoid Receptor
Rinaldi, M. L., Barth, F., Millan, J., Derocq, J., Casellas, P., Congy, C., Oustric, D., Sarran, M., Bouaboula, M., Calandra, B., et al. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37266-0 · Cited by 716
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
Rog, D. J., Nurmikko, T. J., Friede, T., & Young, C. A. (2005) · Neurology · doi:10.1212/01.wnl.0000176753.45410.8b · Cited by 679
Malfait, A. M., Gallily, R., Sumariwalla, P. F., Malik, A. S., Andreakos, E., Mechoulam, R., & Feldmann, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.160105897 · Cited by 669
Cited by
Sorted by citations
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Russo, E. B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01238.x · Cited by 1,535
De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., Stott, C. G., & Di Marzo, V. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01166.x · Cited by 946
Antioxidative and Anti-Inflammatory Properties of Cannabidiol
Atalay, S., Jarocka-Karpowicz, I., & Skrzydlewska, E. (2019) · Antioxidants · doi:10.3390/antiox9010021 · Cited by 889
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb
Izzo, A. A., Borrelli, F., Capasso, R., Marzo, V. D., & Mechoulam, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.07.006 · Cited by 879
Cannabidiol: State of the art and new challenges for therapeutic applications
Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., Abate, M., Faggiana, G., Proto, M., Fiore, D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.041 · Cited by 664
Molecular Targets of Cannabidiol in Neurological Disorders
Bih, C. I., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M. L., & Whalley, B. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0377-3 · Cited by 602
Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
Burstein, S. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.01.059 · Cited by 573
Cannabis, a complex plant: different compounds and different effects on individuals
Atakan, Z. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312457586 · Cited by 612
Recent developments in anti‐inflammatory natural products
Gautam, R., & Jachak, S. M. (2009) · Medicinal Research Reviews · doi:10.1002/med.20156 · Cited by 482
Ligresti, A., PETROCELLIS, L. D., & Marzo, V. D. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 505
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
Zuardi, A. W. (2008) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462008000300015 · Cited by 421
Gregorio, D. D., McLaughlin, R. J., Posa, L., Ochoa‐Sanchez, R., Enns, J. P., López-Canul, M., Aboud, M. K., Maione, S., Comai, S., & Gobbi, G. (2018) · Pain · doi:10.1097/j.pain.0000000000001386 · Cited by 413
Qin, N., Neeper, M. P., Liu, Y., Hutchinson, T. L., Lubin, M. L., & Flores, C. M. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0504-08.2008 · Cited by 403
Cannabinoids and Pain: New Insights From Old Molecules
Vučković, S., Srebro, D., Vujović, K. S., Vučetić, Č., & Prostran, M. S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01259 · Cited by 440
PETROCELLIS, L. D., Vellani, V., Moriello, A. S., Marini, P., Magherini, P. C., Orlando, P., & Marzo, V. D. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.134809 · Cited by 337
PETROCELLIS, L. D., Orlando, P., Moriello, A. S., Aviello, G., Stott, C. G., Izzo, A. A., & Marzo, V. D. (2011) · Acta Physiologica · doi:10.1111/j.1748-1716.2011.02338.x · Cited by 326
Esposito, G., Scuderi, C., Savani, C., Steardo, L., De Filippis, D., Cottone, P., Iuvone, T., Cuomo, V, & Steardo, L. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707337 · Cited by 308
Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside
Rahn, E. J., & Hohmann, A. G. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.08.002 · Cited by 305
Transdermal cannabidiol reduces inflammation and pain‐related behaviours in a rat model of arthritis
Hammell, D. C., Zhang, L., Ma, F., Abshire, S. M., McIlwrath, S. L., Stinchcomb, A. L., & Westlund, K. N. (2015) · European Journal of Pain · doi:10.1002/ejp.818 · Cited by 320
Immune Responses Regulated by Cannabidiol
Nichols, J. M., & Kaplan, B. L. F. (2019) · Cannabis and Cannabinoid Research · doi:10.1089/can.2018.0073 · Cited by 308
Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors
Xiong, W., Cui, T., Cheng, K., Yang, F., Chen, S.-R., Willenbring, D., Guan, Y., Pan, H., Ren, K., Xu, Y., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20120242 · Cited by 290
Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action
Mlost, J., Bryk, M., & Starowicz, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228870 · Cited by 315
Ward, S. J., McAllister, S. D., Kawamura, R., Murase, R., Neelakantan, H., & Walker, E. A. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12439 · Cited by 287
Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies
Finn, D. P., Haroutounian, S., Hohmann, A. G., Krane, E. J., Soliman, N., & Rice, A. S. C. (2021) · Pain · doi:10.1097/j.pain.0000000000002268 · Cited by 280
Baron, E. P. (2018) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13345 · Cited by 268
Baron, E. P. (2015) · Headache The Journal of Head and Face Pain · doi:10.1111/head.12570 · Cited by 219
Inhibition of Recombinant Human T-type Calcium Channels by Δ9-Tetrahydrocannabinol and Cannabidiol
Ross, H., Napier, I. A., & Connor, M. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707104200 · Cited by 203
Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders
Masataka, N. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.02466 · Cited by 157
Borrelli, F., Aviello, G., Romano, B., Orlando, P., Capasso, R., Maiello, F., Guadagno, F., Petrosino, S., Capasso, F., Marzo, V. D., et al. (2009) · Journal of Molecular Medicine · doi:10.1007/s00109-009-0512-x · Cited by 199
Ribeiro, A., Ferraz-de-Paula, V., Pinheiro, M. L., Vitoretti, L. B., Mariano-Souza, D. P., Quinteiro-Filho, W. M., Akamine, A. T., de Almeida, V. I., Quevedo, J., Dal‐Pizzol, F., et al. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.12.043 · Cited by 190
Time-dependent vascular actions of cannabidiol in the rat aorta
O’Sullivan, S. E., Sun, Y., Bennett, A. J., Randall, M. D., & Kendall, D. A. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.03.010 · Cited by 185
Baron, E. P., Lucas, P., Eades, J., & Hogue, O. (2018) · The Journal of Headache and Pain · doi:10.1186/s10194-018-0862-2 · Cited by 188
Valsecchi, A. E., Franchi, S., Panerai, A. E., Rossi, A., Sacerdote, P., & Colleoni, M. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.10.060 · Cited by 176
Henshaw, F. R., Dewsbury, L. S., Lim, C. K., & Steiner, G. Z. (2021) · Cannabis and Cannabinoid Research · doi:10.1089/can.2020.0105 · Cited by 184
King, K. M., Myers, A. M., Soroka‐Monzo, A. J., Tuma, R. F., Tallarida, R. J., Walker, E. A., & Ward, S. J. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13887 · Cited by 156
Citti, C., Linciano, P., Panseri, S., Vezzalini, F., Forni, F., Vandelli, M. A., & Cannazza, G. (2019) · Frontiers in Plant Science · doi:10.3389/fpls.2019.00120 · Cited by 155
The Polypharmacological Effects of Cannabidiol
Castillo-Arellano, J. I., Canseco-Alba, A., Cutler, S. J., & León, F. (2023) · Molecules · doi:10.3390/molecules28073271 · Cited by 172
Molecular and Cellular Mechanisms of Action of Cannabidiol
Naya, N. M., Kelly, J., Corna, G., Golino, M., Abbate, A., & Toldo, S. A. (2023) · Molecules · doi:10.3390/molecules28165980 · Cited by 169
Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., Dupré, D. J., & Denovan‐Wright, E. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.557025 · Cited by 141
Valsecchi, A. E., Franchi, S., Panerai, A. E., Sacerdote, P., Trovato, A. E., & Colleoni, M. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05614.x · Cited by 137
Cannabinoids, Endocannabinoids, and Related Analogs in Inflammation
BURSTEIN, S. H., & Zurier, R. B. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9084-5 · Cited by 139
Kopustinskienė, D. M., Masteiková, R., Lažauskas, R., & Bernatonienė, J. (2022) · Antioxidants · doi:10.3390/antiox11040660 · Cited by 155
Alzheimer's disease; taking the edge off with cannabinoids?
Campbell, V. A., & Gowran, A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707446 · Cited by 132
Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues
Russo, E. B. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00309 · Cited by 128
Hegde, V. L., Nagarkatti, P. S., & Nagarkatti, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018281 · Cited by 129
Rodríguez-Muñoz, M., Onetti, Y., Cortés‐Montero, E., Garzón, J., & Sánchez‐Blázquez, P. (2018) · Molecular Brain · doi:10.1186/s13041-018-0395-2 · Cited by 127
Cannabidiol, extracted fromCannabis sativa, selectively inhibits inflammatory hypermotility in mice
Capasso, R., Borrelli, F., Aviello, G., Romano, B., Scalisi, C., Capasso, F., & Izzo, A. A. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.177 · Cited by 122
DeLong, G. T., Wolf, C. E., Poklis, A., & Lichtman, A. H. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.05.019 · Cited by 110
Review on clinical studies with cannabis and cannabinoids 2005-2009
Hazekamp, A., & Grotenhermen, F. (2010) · Cited by 110
The Role of Cannabidiol (CBD) in Chronic Pain Management: An Assessment of Current Evidence
Boyaji, S., Merkow, J. S., Elman, R. N. M., Kaye, A. D., Yong, R. J., & Urman, R. D. (2020) · Current Pain and Headache Reports · doi:10.1007/s11916-020-0835-4 · Cited by 136
Access to cannabidiol without a prescription: A cross-country comparison and analysis
McGregor, I. S., Cairns, E. A., Abelev, S. V., Cohen, R., Henderson, M., Couch, D., Arnold, J. C., & Gauld, N. J. (2020) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2020.102935 · Cited by 114
Comelli, F., Giagnoni, G., Bettoni, I., Colleoni, M., & Costa, B. (2008) · Phytotherapy Research · doi:10.1002/ptr.2401 · Cited by 103
Self-citationNatural Products Evaluated in Neuropathic Pain Models ‐ A Systematic Review
Quintans, J. D. S. S., Antoniolli, Â. R., Almeida, J. R. G. D. S., Santana‐Filho, V. J., & Quintans‐Júnior, L. J. (2013) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12178 · Cited by 103
Cannabis constituent synergy in a mouse neuropathic pain model
Casey, S. L., Atwal, N., & Vaughan, C. W. (2017) · Pain · doi:10.1097/j.pain.0000000000001051 · Cited by 105
Use of cannabidiol (CBD) for the treatment of chronic pain
Urits, I., Gress, K. L., Charipova, K., Habib, K., Lee, D. M., Lee, C. S., Jung, J. W., Kassem, H., Cornett, E. M., Paladini, A., et al. (2020) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2020.06.004 · Cited by 111
Endocannabinoids: A unique opportunity to develop multitarget analgesics
Maione, S., Costa, B., & Marzo, V. D. (2013) · Pain · doi:10.1016/j.pain.2013.03.023 · Cited by 104
Cannabis: a multifaceted plant with endless potentials
Fordjour, E., Manful, C. F., Sey, A. A., Javed, R., Pham, T. H., Thomas, R., & Cheema, M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1200269 · Cited by 109
Stanley, C. P., Hind, W. H., Tufarelli, C., & O’Sullivan, S. E. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv179 · Cited by 100
Cassol-Jr, O. J., Comim, C. M., Silva, B. R., Hermani, F. V., Constantino, L. S., Felisberto, F., Petronilho, F., Hallak, J. E. C., De Martinis, B. S., Zuardi, A. W., et al. (2010) · Brain Research · doi:10.1016/j.brainres.2010.06.023 · Cited by 94
Medical cannabis ‒ the Canadian perspective
Ramkellawan, S., Bober, S., Mindra, S., Moreau, J. M., & Ko, G. D. (2016) · Journal of Pain Research · doi:10.2147/jpr.s98182 · Cited by 91
TRP channels: a journey towards a molecular understanding of pain
Rosenbaum, T., Morales‐Lázaro, S. L., & Islas, L. D. (2022) · Nature reviews. Neuroscience · doi:10.1038/s41583-022-00611-7 · Cited by 91
Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease
Silvestro, S., Schepici, G., Bramanti, P., & Mazzon, E. (2020) · Molecules · doi:10.3390/molecules25215186 · Cited by 93
Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects
Pauli, C. S., Conroy, M., Heuvel, B. D. V., & Park, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00063 · Cited by 90
Hegde, V. L., Singh, U. P., Nagarkatti, P. S., & Nagarkatti, M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401844 · Cited by 89
Wu, H., Chu, R., Wang, C., Lee, C.-Y., Lin, S., & Jan, T. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2007.09.012 · Cited by 85
The Pharmacology and Therapeutic Potential of Plant Cannabinoids
Cascio, M. G., Pertwee, R. G., & Marini, P. (2017) · Springer eBooks · doi:10.1007/978-3-319-54564-6_9 · Cited by 94
A molecular basis for the anti‐inflammatory and anti‐fibrosis properties of cannabidiol
Sunda, F., & Arowolo, A. (2020) · The FASEB Journal · doi:10.1096/fj.202000975r · Cited by 91
Cannabidiol modulation of oxidative stress and signalling
Pereira, S. R., Hackett, B., O’Driscoll, D. N., Sun, M. C., & Downer, E. J. (2021) · Neuronal Signaling · doi:10.1042/ns20200080 · Cited by 97
Cannabinoids: Novel Medicines for the Treatment of Huntingtons Disease
Sagredo, O., Pazos, M. R., Valdeolivas, S., & Fernández‐Ruíz, J. (2011) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488912798842278 · Cited by 82
Maccarrone, M., Maldonado, R. J., Casas, M., Henze, T., & Centonze, D. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1292849 · Cited by 83
Tie, L., Yang, H., An, Y., Liu, S., Han, J., Xu, Y., Hu, M., Li, W., Chen, A. F., Lin, Z.-B., et al. (2012) · Cellular Physiology and Biochemistry · doi:10.1159/000338512 · Cited by 79
Filippis, D. D., Iuvone, T., D’Amico, A., Esposito, G., Steardo, L., Herman, A. G., Pelckmans, P. A., Winter, B. Y. D., & Man, J. G. D. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2008.01114.x · Cited by 80
Cannabinoids: new promising agents in the treatment of neurological diseases.
Giacoppo, S., Mandolino, G., Galuppo, M., Bramanti, P., & Mazzon, E. (2014) · Molecules · doi:10.3390/molecules191118781 · Cited by 79
Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?
Zlebnik, N. E., & Cheer, J. F. (2016) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-014038 · Cited by 82
Pitfalls in the analysis of phytocannabinoids in cannabis inflorescence
Citti, C., Russo, F., Sgrò, S., Gallo, A., Zanotto, A., Forni, F., Vandelli, M. A., Laganà, A., Montone, C. M., Gigli, G., et al. (2020) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-020-02554-3 · Cited by 79
Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands
Davis, M. P. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.918603 · Cited by 81
McCarberg, B. H., & Barkin, R. L. (2007) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3180a5e581 · Cited by 76
The evolving science of phytocannabinoids
Reekie, T. A., Scott, M., & Kassiou, M. (2017) · Nature Reviews Chemistry · doi:10.1038/s41570-017-0101 · Cited by 78
A Balanced Approach for Cannabidiol Use in Chronic Pain
Argueta, D. A., Ventura, C. M., Kiven, S. B., Sagi, V., & Gupta, K. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00561 · Cited by 78
Comelli, F., Bettoni, I., Colleoni, M., Giagnoni, G., & Costa, B. (2009) · Phytotherapy Research · doi:10.1002/ptr.2806 · Cited by 75
“Redundancy” of Endocannabinoid Inactivation: New Challenges and Opportunities for Pain Control
Piscitelli, F., & Marzo, V. D. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300015x · Cited by 75
Britch, S. C., Goodman, A. G., Wiley, J. L., Pondelick, A. M., & Craft, R. M. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.263319 · Cited by 79
Topical and Systemic Cannabidiol Improves Trinitrobenzene Sulfonic Acid Colitis in Mice
Schicho, R., & Storr, M. (2012) · Pharmacology · doi:10.1159/000336871 · Cited by 80
McCartney, D., Benson, M. J., Desbrow, B., Irwin, C. G., Suraev, A. S., & McGregor, I. S. (2020) · Sports Medicine - Open · doi:10.1186/s40798-020-00251-0 · Cited by 79
Silva-Cardoso, G. K., Lazarini-Lopes, W., Hallak, J. E. C., Crippa, J. A. S., Zuardi, A. W., Garcia‐Cairasco, N., & Leite‐Panissi, C. R. A. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108712 · Cited by 81
Pharmacological effects of cannabidiol by transient receptor potential channels
Etemad, L., Karimi, G., Alavi, M. S., & Roohbakhsh, A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120582 · Cited by 73
Role of TNF-alpha during central sensitization in preclinical studies
Andrade, P., Visser-Vandewalle, V. E. R. M., Hoffmann, C., Steinbusch, H. W. M., Daemen, M. A. R. C., & Hoogland, G. (2011) · Neurological Sciences · doi:10.1007/s10072-011-0599-z · Cited by 69
Li, H., Kong, W., Chambers, C. R., Yu, D., Ganea, D., Tuma, R. F., & Ward, S. J. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.02.016 · Cited by 69
Cannabidiol from inflorescences of Cannabis sativa L.: Green extraction and purification processes
Marzorati, S., Friscione, D., Picchi, E., & Verotta, L. (2020) · Industrial Crops and Products · doi:10.1016/j.indcrop.2020.112816 · Cited by 67
Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?
Crippa, J. A. S., Hallak, J. E. C., Zuardi, A. W., Guimarães, F. S., Tumas, V., & SANTOS, R. G. D. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-00982-6 · Cited by 66
Dunn, S. L., Wilkinson, J. M., Crawford, A., Bunning, R. A. D., & Le Maitre, C. L. (2016) · Cannabis and Cannabinoid Research · doi:10.1089/can.2015.0001 · Cited by 62
Giacoppo, S., Galuppo, M., Pollastro, F., Grassi, G., Bramanti, P., & Mazzon, E. (2015) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/s40199-015-0131-8 · Cited by 62
Xu, C., Xu, W., Xu, H., Xiong, W., Gao, Y., Li, G., Liu, S., Xie, J., Tu, G., Peng, H., et al. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.10.007 · Cited by 60
Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions
Henson, J. D., Vitetta, L., & Hall, S. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-01020-z · Cited by 62
Cannabidiol and brain function: current knowledge and future perspectives
Schouten, M., Dalle, S., Mantini, D., & Koppo, K. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1328885 · Cited by 64
Cahill, S. P., Lunn, S. E., Diaz, P. L., & Page, J. E. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.626853 · Cited by 56
Zhang, H.-X. B., & Bean, B. P. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.3216-20.2021 · Cited by 55
Shebaby, W. N., Saliba, J., Faour, W. H., Ismail, J., Hage, M. E., Daher, C. F., Taleb, R. I., Nehmeh, B., Dagher, C., Chrabieh, E. E., et al. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113743 · Cited by 55
Cannabinoids and Inflammations of the Gut-Lung-Skin Barrier
Scheau, C., Căruntu, C., Bădărău, I. A., Scheau, A.-E., Docea, A. O., Călina, D. C., & Căruntu, A. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060494 · Cited by 54
Neuroinflammation and neuroprogression in depression: Effects of alternative drug treatments
Richardson, B., MacPherson, A., & Bambico, F. R. (2022) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2022.100554 · Cited by 57
Metadata
- Authors
- Costa, B., Trovato, A. E., Comelli, F., Giagnoni, G., & Colleoni, M.
- Affiliations
- University of Milano-Bicocca (IT)
- University of Milan (IT)
- Corresponding author
- Costa, Barbara
- ORCID
- Costa, Barbara
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2007-02
- Volume
- 556
- Issue
- 1-3
- Pages
- 75-83
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W1967303451
- Cited by
- 395
- References
- 46
- Citations by year
- 2026: 22 · 2025: 28 · 2024: 37 · 2023: 42 · 2022: 37 · 2021: 43 · 2020: 35 · 2019: 20 · 2018: 17 · 2017: 16 · 2016: 14 · 2015: 8 · 2014: 9 · 2013: 11 · 2012: 14
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Funders
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- cannabidiol, neuropathic pain, inflammatory pain, chronic constriction injury, complete Freund's adjuvant, hyperalgesia, capsazepine, vanilloid receptor, prostaglandin E2, nitric oxide, endothelial nitric oxide synthase, glutathione, NF-κB, TNF-α, anti-inflammatory activity, oral administration
- MeSH terms
- Administration, Oral, Animals, Cannabidiol, Cannabis, Capsaicin, Chronic Disease, Freund's Adjuvant, Hyperalgesia, Inflammation, Lipid Peroxides, Male, Nitric Oxide, Pain, Pain Measurement, Tumor Necrosis Factor-alpha, Dinoprostone, NF-kappa B, Rats, Wistar, Nitric Oxide Synthase, Sciatic Neuropathy, Rats, Cannabinoid Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review